The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF.

摘要: BACKGROUND. Lung cancer is the leading source of mortality and spending. However, value spending on treatment lung has not been conclusively demonstrated. The authors evaluated medical care between 1983 1997 for nonsmall cell in elderly US population. METHODS. The used Surveillance, Epidemiology, End Results (SEER) data to calculate life expectancy after diagnosis over period 1997. Direct costs detection were determined by using Part A B reimbursements from Continuous Medicare History Sample File (CMHSF) data. CMHSF SEER linked lifetime time interest. RESULTS. Life improved minimally, with an average increase approximately 0.60 months. Total rose $20,157 per patient real, ie, adjusted inflation, 2000 dollars early 1980s mid-1990s, a cost-effectiveness ratio $403,142 year (LY). was $143,614 localized cancer, $145,861 regional $1,190,322 metastatic cancer. CONCLUSIONS. The higher than traditional thresholds define cost-effective care. most favorable results persons diagnosed stage cancer. These suggested caution when encouraging more intensive patients without first considering tradeoffs this therapy its potential effects and/or quality life. Cancer 2007. © 2007 American Society.